登录后查看消息通知
搜索
常见问题
消息
登录
首页
/
数据集
/
ABA-1L vs. TNFi-1L: Patient characteristics of matched populations.
ABA-1L vs. TNFi-1L: Patient characteristics of matched populations.
收藏
Figshare
2022-11-16 更新
2026-04-28 收录
风湿免疫治疗对比
生物制剂疗效
数据链接:
https://figshare.com/articles/dataset/ABA-1L_vs_TNFi-1L_Patient_characteristics_of_matched_populations_/21567304
数据链接
链接失效反馈
官方服务:
问题咨询
购买咨询
在线客服
NEW
资源简介:
ABA-1L vs. TNFi-1L: Patient characteristics of matched populations.
应用场景:
创建时间:
2022-11-16
相关数据集
Head-to-head comparison of risankizumab and ixekizumab in GenPs
银屑病治疗
生物制剂疗效
Methodology; Figure 1c; Table 1
NIAID Data Ecosystem
9
0
Anti -TNFα agents in preventing the postoperative recurrence of Crohn’s disease: Do they still play a role in the biological era?
克罗恩病术后复发
生物制剂疗效
Approximately half of patients with Crohn’s disease (CD) may inevitably receive surgical intervention as the disease progress. However, about 75% of CD patients will experience postoperative recurrenc
Taylor & Francis Group
2024-03-01 更新
4
0
Comparison of etanercept, adalimumab, and infliximab benefit across studies.
生物制剂疗效
自身免疫疾病治疗
Comparison of etanercept, adalimumab, and infliximab benefit across studies.
Figshare
2020-03-23 更新
1
0
Table 3: laboratory and clinical response to ustekinumab
生物制剂疗效
临床评估
laboratory and clinical response to ustekinumab
Figshare
2021-05-26 更新
4
0
Demographics of patients included in the exploratory analysis of pre- vs. post-biologic therapy and patients without IBD (healthy control).
结肠炎研究
生物制剂疗效
Demographics of patients included in the exploratory analysis of pre- vs. post-biologic therapy and patients without IBD (healthy control).
NIAID Data Ecosystem
2
0
© 2023-2026 上海数据发展科技有限责任公司 版权所有
沪ICP备17003045号-15
沪公网安备31010402336585号
热门搜索
社区交流群
科研交流群
商业服务
数据资源
寻源服务
数据采集
标注服务
数据产品
代理销售
数据领域
凭证登记
数据产品
介绍推广